Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

FDA gives greenlight for new treatment of head and neck cancer

The U.S. Food and Drug Administration has approved colon cancer drug Erbitux to treat head and neck cancer after results of a large clinical trial showed the drug prolonged survival by 20 months.

5 Mar 2006

C-reactive protein helps identify progressive precancerous lesions in the lung

C-reactive protein (CRP), a biomarker for inflammation in the blood, can help to identify individuals whose abnormal precancerous lesions will advance closer to invasive lung cancer.

1 Mar 2006

Human papillomavirus the main risk factor for cervical adenocarcinoma

Human papillomavirus (HPV) was found to be the main risk factor associated with increased incidence of an unusual type of cervical cancer called cervical adenocarcinoma, according to a study in the March 1 issue of the Journal of the National Cancer Institute.

1 Mar 2006

Papillary lesions of the breast should be surgically excised to avoid missing a cancer

Certain breast lesions diagnosed as benign on core needle biopsy have cancer at surgical excision and thus should be removed, according to a study appearing in the March issue of Radiology.

28 Feb 2006

Cathepsin inhibitors as cancer therapies

In the March 1 issue, Drs. Johanna Joyce (MSKCC), Douglas Hanahan (UCSF) and colleagues lend new insight into how broad-spectrum cysteine cathepsin inhibitors combat pancreatic cancer, and provide new data to help refine the design of more precisely targeted anti-cathepsin therapies.

17 Feb 2006

MRI can detect breast disease missed by mammography

Researchers have found that mammography coupled with magnetic resonance imaging (MRI) is extremely sensitive in the detection of ductal carcinoma in situ (DCIS). DCIS, or early stage breast carcinoma, is a pre-invasive malignancy and MRI may help identify this type of disease, which may not be visible on a mammogram.

16 Feb 2006

Protein associated with growth of tumors may prevent the spread of cancer

A protein associated with the growth of head and neck tumors may be a tumor suppressor that could prevent the spread of cancer when it is expressed above normal levels, according to a study published in the Journal of the National Cancer Institute (JNCI).

13 Feb 2006

Lamivudine helps avoid Hepatitis B relapse during chemotherapy

A new study on treating hepatitis B patients who have cancer with an antiviral drug at the same time as they undergo chemotherapy found that the treatment helped prevent relapse of hepatitis B.

12 Feb 2006

Breast ducts - A new site for cancer treatment!

Johns Hopkins Kimmel Cancer Center researchers are studying whether delivering chemotherapy drugs directly to breast "plumbing" might make treatment of early breast cancer easier on the patient and at least as good as surgery or radiation.

26 Jan 2006

Researchers use new approach to 'break the code' for liver cancer test

Scientists at Birmingham University are using cutting edge technologies to move closer to a blood test that will improve early diagnosis of liver cancer in high risk groups, according to research published in the British Journal of Cancer.

25 Jan 2006

Identification of Gli protein degradation signals that directly affect tumor latency

Dr. Anthony E. Oro and colleagues (Stanford University) have identified two key Gli protein degradation signals that directly affect tumor latency in a mouse model of human skin cancer.

22 Jan 2006

TCF21 gene shown to be a tumor suppressor

Researchers have identified a new and unusual tumor suppressor gene that may be important in cancers of the lung and head and neck. The study shows that restoring the inactivated gene can slow the growth of tumor cells.

18 Jan 2006

Fatigue in long-term breast carcinoma survivors

Up to one third of women treated for breast cancer report fatigue symptoms up to 10 years after diagnosis, according to a new study.

9 Jan 2006

Targeted cancer therapies: Another step forward

While it is clear that the treatment of cancer has already begun to undergo a paradigm shift with the inclusion of innovative targeted therapies into current regimens, it would be wrong to assume these products will entirely replace traditional chemotherapy as the standard treatment for cancer sufferers.

22 Dec 2005

Targeted cancer therapies: Another step forward

22 Dec 2005

Imatinib mesylate (Gleevec) may not be effective at treating kidney cancer

Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with gastrointestinal stromal cancers (GISTs), is not likely to be effective for patients with high grade renal cell carcinoma -- the most aggressive kidney cancer.

22 Dec 2005

65% of ovarian cancer cells sideline body's defences

Ovarian cancer tumour cells use two separate mechanisms to evade the body’s defensive reaction - and in so doing also elude a newly discovered counteraction from the surrounding tissue.

15 Dec 2005

Study finds AKT blocks cancer cell motility

PIn investigating the molecular mechanisms of cancer cell motility - the unique property that enables cancer to spread from its primary origin to other parts of the body - researchers have uncovered a surprising role for the AKT/PKB (protein kinase B) enzyme

26 Nov 2005

Largest hepatitis-C U.S. study defines optimal therapy

Final results of the WIN-R trial,[1] the largest hepatitis C study conducted in U.S. patients, showed that weight-based REBETOL (ribavirin, USP) in combination therapy with PEG-INTRON (peginterferon alfa-2b) achieved significantly higher rates of sustained virologic response (SVR)[2] and lower rates of relapse compared to the combination therapy using a flat dose of ribavirin.

14 Nov 2005